CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hubei Biocause Heilen Pharmacetcl Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hubei Biocause Heilen Pharmacetcl Co Ltd
No. 122, Yangwan Road
Phone: +86 7242223303p:+86 7242223303 JINGMEN, HUB  448000  China Ticker: 301211301211
Business Summary
Hubei Biocause Heilen Pharmaceutical Co Ltd is a China-based company primarily engaged in the research, development, production, and sales of chemical active pharmaceutical ingredients (APIs) and intermediates. The Company also engages in the research, development, production, and sales of pharmaceutical formulations and provides contract development and manufacturing organization (CDMO) services. The API and intermediate business includes nonsteroidal anti-inflammatory APIs, cardiovascular APIs, antitumor APIs, and anticholinergic APIs and intermediates. The formulation business mainly utilizes APIs produced in-house to develop antipyretic analgesics, cardiovascular APIs, and anti-infective formulations. The CDMO service provides services from preclinical to commercialization, including process development, pilot-scale production, commercial manufacturing, method validation, and registration submission.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board ZhigangCheng 49 6/1/2020 6/1/2020
Chief Financial Officer TinghaoYi 50 6/1/2020 6/1/2020
General Manager QunLiang 52 6/1/2020 6/1/2020
11 additional Officers and Directors records available in full report.

General Information
Number of Employees: 952 (As of 12/31/2025)
Outstanding Shares: 417,600,000 (As of 3/31/2026)
Shareholders: 20,598
Stock Exchange: SHE
Fax Number: +86 7242211900


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 13, 2026